Mitani Sangyo (8285) · RiskMitigated
Impact on active pharmaceutical ingredient sales from lower customer demand for imported products and merchandise
First written in FY2022-Q1. 1 of 3 entries say "Restated". Latest entry: FY2024-Q2.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Decline in API sales due to reduced customer demand for imported goods and merchandiseA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024-Q2MitigatedAnnual report
「API revenue increased because customer demand for imported products was strong.」
The situation changed from lower customer demand for imported products and merchandise, as described in the previous fiscal year, to higher sales driven by strong customer demand for imported products. - FY2022-Q2RestatedAnnual report
「Although proprietary products remained solid, API revenue declined because customer demand for imported products and merchandise decreased.」
While the company's own products remain solid, lower customer demand for imported products and merchandise continues to be a factor behind the decline in active pharmaceutical ingredient sales. - FY2022-Q1First statedAnnual report
「Although proprietary products performed well, API revenue declined because customer demand for imported products and merchandise decreased.」
While the company's own products performed well, lower customer demand for imported products and merchandise actually resulted in a decline in sales of pharmaceutical active ingredients.